Showing results (341-350 of 355) with videos related to

Sort By:
Pageof 36
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)J Mateo, D Chakravarty, R Dienstmann, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Trials|September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trialDafna D Gladman, Philip J Mease, Paul Bird, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Lancet. Rheumatology|January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesPhilip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Kidney International|October 4, 2013
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in childrenAditi Sinha, Ashima Gulati, Savita Saini, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Pageof 36